Key Events This Week
2 Feb: Technical momentum shifts amid mixed market signals
5 Feb: Downgrade to Sell rating by MarketsMOJO
6 Feb: Bearish momentum confirmed with technical downgrade
6 Feb: Week closes at Rs.4,001.90 (-0.40%) vs Sensex +1.51%
Feb 06
BSE+NSE Vol: 9.13 k
2 Feb: Technical momentum shifts amid mixed market signals
5 Feb: Downgrade to Sell rating by MarketsMOJO
6 Feb: Bearish momentum confirmed with technical downgrade
6 Feb: Week closes at Rs.4,001.90 (-0.40%) vs Sensex +1.51%

Sanofi India Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 5 February 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite strong management efficiency and attractive valuation metrics, the stock’s long-term growth outlook remains subdued, prompting a cautious stance for investors.
Read full news article
Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent performance, coupled with mixed signals from MACD, RSI, and moving averages, suggests increasing caution for investors amid a challenging market backdrop.
Read full news article
Sanofi India Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. While the stock’s weekly indicators suggest a mild recovery, monthly trends remain subdued, underscoring the challenges facing this Pharmaceuticals & Biotechnology player amid broader market volatility.
Read full news article
27 Jan: MarketsMOJO upgrades Sanofi India Ltd to Hold amid mixed financial signals
29 Jan: Technical momentum shifts to bearish trends despite short-term bullish indicators
30 Jan: Stock closes the week at ₹4,017.85, down 1.29% for the week

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock faces mounting pressure from moving averages and monthly technicals, reflecting challenges in sustaining upward price momentum.
Read full news article
Sanofi India Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its overall outlook. This change is driven by a combination of factors including improved quality metrics, attractive valuation, stable financial trends, and mixed technical signals. Despite some challenges in long-term growth, the company’s strong management efficiency and favourable dividend yield have contributed to this reassessment.
Read full news article
Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3976.4 on 21 Jan 2026, marking a continuation of the stock’s downward trajectory over recent sessions and reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Read full news article
Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news articlePlease find enclosed copies of the Notice to Shareholders of the Company published today i.e. 9th January 2026 in newspapers Business Standard (English) and Sakal (Marathi).
Please find enclosed Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the period ended 31st December 2025.
Please find enclosed disclosure received under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
No Upcoming Board Meetings
Sanofi India Ltd has declared 750% dividend, ex-date: 07 Nov 25
No Splits history available
No Bonus history available
No Rights history available